Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Another welfare services country is piloting Nightingale's technology

Nightingale Health

Summary

  • Nightingale Health announced a pilot project with North Karelia wellbeing services county to integrate its blood analysis technology into health check-ups for unemployed individuals, aiming for a cost-effective preventive healthcare model.
  • This initiative marks Nightingale's second collaboration with Finnish public healthcare, following a similar project with South Savo, indicating growing public sector interest despite no immediate financial impact.
  • The pilot, set to begin testing in the first half of 2026, targets statutory health check-ups, aligning with Nightingale's strategy to integrate into existing healthcare processes without major changes.
  • The project's success could enhance Nightingale's reference value, potentially leading to broader adoption in North Karelia or other counties, although its short-term financial impact is expected to be minor.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 12/18/2025 at 8:10 pm EET.

Nightingale Health announced on Thursday that the North Karelia wellbeing services county is piloting the company's blood analysis technology as part of health check-ups for unemployed individuals. The project aims to develop a cost-effective and impactful operating model for preventive healthcare. The project will start immediately with preliminary preparations, and the actual testing is scheduled to begin in the first half of 2026. The news is a positive signal of the company's technology being of interest to the public sector, but due to its pilot nature, it has no immediate impact on our forecasts.

A step towards broader public sector adoption

The project now announced is Nightingale's second opening in Finnish public healthcare, as the company has previously reported similar cooperation with the South Savo wellbeing services county. We consider the public sector a significant but slowly developing potential market for Nightingale. The new pilot project is an encouraging sign of the interest Nightingale's technology has generated in welfare areas struggling with cost pressures. We originally commented on the company's public sector initiative here in June.

The target group selected for the North Karelia wellbeing services county pilot, health check-ups for unemployed individuals, is a statutory service. This provides a natural and existing process for piloting new technology without massive changes to treatment pathways. This is in line with Nightingale's strategy, which aims to integrate into existing healthcare routines and value chains.

The project will proceed to the testing phase in the first half of 2026, and its financial impact is, in our view, minor in the short term. However, the success of the pilot is important for its reference value, as it could open doors for wider use in North Karelia or other wellbeing services counties in the future. We will be following with interest how the pilot progresses and whether Nightingale can demonstrate concrete benefits that would lead to a permanent and broader commercial agreement.

 

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures19.09.2025

202526e27e
Revenue4.77.98.8
growth-%7.7 %67.2 %12.1 %
EBIT (adj.)-19.4-17.3-15.2
EBIT-% (adj.)-413.7 %-220.4 %-172.8 %
EPS (adj.)-0.30-0.27-0.24
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Greetings to the thread, Regarding company coverage, some news: we are transferring the primary responsibility for Nightingale mainly to me....
2/16/2026, 2:51 PM
by Antti Siltanen
47
I don’t want to manipulate the stock price, but many don’t truly know NG’s potential/history. I know this very well myself, which is why I created...
2/11/2026, 4:55 PM
by Ossi
16
Relevant AI players mentioned, NH included.
2/10/2026, 7:04 AM
by Puutaheinää
13
It looks like the report was already published at 01:00. So, at a quick glance, there is a desire for a centralized system in Finland where ...
2/10/2026, 6:46 AM
by Salkkumies
5
This Sitra development was news to me. Today is indeed the launch event for the national health data future model proposal, which is sold out...
2/10/2026, 6:36 AM
by Salkkumies
2
I certainly take this as clearly positive news; at least for me, it wasn’t a “foregone conclusion” that we wouldn’t end up in the FDA pipeline...
2/10/2026, 6:25 AM
by Puutaheinää
2
Inderes Nightingalelle edistysaskel New Yorkissa - Inderes New Yorkin laboratoriolupa mahdollistaa testien tarjoamisen terveydenhuollolle ilman...
2/10/2026, 5:45 AM
by Pertti
6
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.